Sipuleucel-T and immunotherapy in the treatment of prostate cancer

Expert Opinion on Biological Therapy

Volumn 14, Issue 5, 2014, Pages 709-719

  Dawson, Nancy A ^a   Roesch, Erin E ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

Castration resistance; Cytotoxic T lymphocyte antigen 4; Immunotherapy; Programmed death 1; Prostate cancer; ProstVac VF; Sipuleucel T

Indexed keywords

ABIRATERONE ACETATE; ANTIANDROGEN; CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; MONOCLONAL ANTIBODY; PREDNISONE; PROGRAMMED DEATH 1 LIGAND 1; PROSTATE SPECIFIC ANTIGEN; RILIMOGENE GALVACIREPVEC; SIPULEUCEL T; TISSUE EXTRACT;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; ANTIBODY RESPONSE; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CELL CYCLE CHECKPOINT; CELLULAR IMMUNITY; DISEASE COURSE; DRUG COST; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG UTILIZATION; HUMAN; IMMUNE RESPONSE; LYMPHOCYTIC INFILTRATION; MALE; MULTIMODALITY CANCER THERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; IMMUNOTHERAPY; PROSTATIC NEOPLASMS;

CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS; TISSUE EXTRACTS;

EID: 84898746976     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2014.896897     Document Type: Review

References (86)

1. Cancer Fact & Figures-2013. American Cancer Society. Available from: Www. cancer.org/acs/groups/content/@epidemiologysurveilance/documents/ document/acspc-036845.pdf [Last accessed 1 January 2014]
2. D'Amico AV, Chen MH, Roehl KA, et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004;351:125-35
3. D'Amico AV, Renshaw AA, Sussman B, et al. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005;294:440-7
4. Small EJ, Penson DF, Sartor O. The relationship between symptomatology and treatment selection in metastatic castrate-resistant prostate cancer. Clin Adv Hematol Oncol 2011;9(7 Suppl 13):1-15.Review
5. Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: A systematic review. Int J Clin Pract 2011;65:1180-92
6. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010;327:291-5
7. Holtmeier W, Kabelitz D. Gammadelta T cells link innate and adaptive immune responses. Chem Immunol Allergy 2005;86:151-83
8. Van Luijn MM, Chamuleau ME, Ressing ME, et al. Alternative li-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes. Cancer Immunol Immunother 2010;59:1825-38
9. Abbas AK, Lichtman AH. Immune responses against tumors and transplants. Basic immunology: Functions and disorders of the immune system. 3rd edition. Saunders Elsevier, Philadelphia, PA; 2011
10. Kirkwood JM, Butterfield LH, Tarhini AA, et al. Immunotherapy of cancer in 2012. CA Cancer J Clin 2012;62:309-35
11. Murphy K. Janeway's immunobiology. 8th edition. Garland Science, Taylor & Francis Group, LLC, New York, NY; 2012
12. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144:646-74
13. Krynitz B, Edgren G, Lindelof B, et al. Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970-2008-A Swedish population-based study. Int J Cancer 2013;132:1429-38
14. Guiguet M, Boue F, Cadranel J, et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): A prospective cohort study. Lancet Oncol 2009;10:1152-9
15. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13
16. Galon C, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4
17. National Cancer Institute. NCI dictionary of cancer terms: Immunotherapy. Available from: Www. cancer.gov/dictionary? print=1&cdrid=45729 [Last accessed 25 September 2012]
18. Gulley JL, Madan RA, Arlen PM. Enhancing efficacy of therapeutic vaccinations by combination with other modalities. Vaccine 2002;25(Suppl 2):B89-96
19. Kakimi K, Nakajima J, Wada H. Active specific immunotherapy and cell-Transfer therapy for the treatment of non-small cell lung cancer. Lung Cancer 2009;65:1-8
20. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011;480:480-9
21. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: Mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007;18:977-84
22. Boikos SA, Antonarakis ES. Immmunotherapy for prostate cancer enters its golden age. Clin Med Insights Oncol 2012;6:263-73
23. Liao W, Lin JX, Leonard WJ. IL-2 family cytokines: New insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr Opin Immunol 2011;23:598-604
24. Romo de Vivar Chavez A, de Vera ME, Liang X, et al. The biology of interleukin-2 efficacy in the treatment of patients with renal cell carcinoma. Med Oncol 2009;26(Suppl 1):3-12
25. Stein WD, Gulley JL, Schlom J, et al. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: The growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res 2011;17:907-17
26. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-Targeted immunotherapy in metastatic castration resistant prostate cancer. J Clin Oncol 2010;28:1099-105
27. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22
28. Scott AM, Allison JP, Wolchock JD. Monoclonal antibodies in cancer therapy. Cancer Immun 2012;12:14
29. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;324:235-42
30. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78
31. VanCustem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-64
32. Atkins MB, Kunkel L, Sznol M, et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-Term survival update. Cancer J Sci Am 2000;6(Suppl 1):S11-14
33. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17
34. Hodi FS, O-Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2012;363:711-23
35. Hales RK, Banchereau J, Ribas A, et al. Assessing oncologic benefit in clinical trials of immunotherapy agents. Ann Oncol 2010;21:1944-51
36. Hodi FS, Butler M, Oble DA, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-Associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 2008;105:3005-10
37. Topaliam SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54
38. Hoos A, Eggermont AM, Janetzki S, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010;102:1388-97
39. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148-59
40. Gulley JL, Drake CG. Immunotherapy for prostate cancer: Recent advances, lessons learned, and areas for further research. Clin Cancer Res 2011;17:3884-91
41. Von Mehren M, Arlen P, Gulley J, et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immune response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res 2001;7:1181-91
42. Schlom J, Arlen PM, Gulley JL. Cancer vaccines: Moving beyond current paradigms. Clin Cancer Res 2007;13:3776-82
43. Dawson NA, Pessis DA, McNeel DG, et al. Patients treated with sipuleucel-T who had prior docetaxel had positive immune responses and survival benefit [abstract 263]. The European Multidisciplinary Cancer Congress; Stockholm, Sweden; 2011
44. Small EJ, Lance RS, Redfem CH, et al. A randomized phase II trial of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) plus prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC). American Society for Clinical Oncology Annual Meeting, Chicago, Illinois. J Clin Oncol 2013;31(Suppl):abstract 5047
45. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-27
46. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92
47. Becker JT, Olson BM, Johnson LE, et al. DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-Term T cell response in patients with recurrent prostate cancer. J Immunother 2010;33:639-47
48. Mercader M, Bodner BK, Moser MT, et al. T cell infiltration of the prostate and induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci USA 2001;98:14565-70
49. Drake CG, Doody AD, Mihalyo MA, et al. Androgen ablation mitigates tolerance to a prostate/prostate cancerrestricted antigen. Cancer Cell 2005;7:239-49
50. Sutherlans JS, Goldberg GL, Hammer MV, et al. Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol 2005;175:2741-53
51. Koh YT, Gray A, Higgins SA, et al. Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization. Prostate 2009;69:571-84
52. Arlen PM, Gulley JL, Todd N, et al. Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J Urol 2005;174:539-46
53. Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 2010;10:580-93
54. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSAtargeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:1099-105
55. Madan RA, Gulley JL, Schlom J, et al. Analysis of overall survival in patients with nonmetatsatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res 2008;14:4526-31
56. Lipson EJ, Drake CG. Ipilimumab: An anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 2011;17:6958-69
57. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26
58. Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptordeficient mice. Science 2001;291:319-22
59. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-Agent antiprogrammed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28:3167-75
60. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24:3089-94
61. Higano C, Burch P, Small E, et al. Immunotherapy (APC8015) for androgen independent prostate cancer (AIPC): Final progression and survival data from a second Phase 3 trial. 13th European Cancer Conference; Paris; 2005
62. Dawson N, Petrylak D, Corman J, et al. Cellular and humoral immune system activation by sipuleucl-T: Preliminary data from the OpenACT phase 2 trial. European Society for Medical Oncology Congress; Vienna, Austria; 2012
63. Beer TM, Glode M, Lance R, et al. P10-1, An open-label, multicentre study of sipuelceul-T in men with metastatic castrate-resistance prostate cancer (mCRPC) previously treated with sipuleucel-T: Analysis of immunological data [abstract 2909]. European Cancer Congress; Amsterdam, Netherlands; 2013
64. Mulders P, De Santis M, Fizazi K, et al. Preliminary product parameters from P11-1, a phase 2 open-label trial of sipuleucel-T in European men with metastatic castrate-resistant prostate cancer (mCRPC) [abstract 2900]. European Cancer Congress; Amsterdam, Netherlands; 2013
65. Drake CG, Fan L-Q, Guha Thakurta D, et al. Antigen spread and overall survival in advanced prostate cancer patients after treatment with sipuleucel-T [abstract 88]. Genitourinary Cancers Symposium; San Francisco, California; 2014
66. Nabhan C, Sartor O, Cooperberg MR, et al. Sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC) patients ‡80 years old: Data from PROCEED [abstract 64]. Genitourinary Cancers Symposium; San Francisco, California; 2014
67. Vogelzang NJ, Vacirca J, Kantoff PW, et al. Effect of prior abiraterone acetate or enzalutamide on sipuleucel-T manufacture in PROCEED patients [abstract 185]. Genitourinary Cancers Symposium; San Francisco, California; 2014
68. Finkelstein SE, Nordquist LT, Dakhil SR, et al. Impact of prior radiation treatment on sipuleucel-T product parameters in PROCEED patients [abstract 183]. Genitourinary Cancers Symposium; San Francisco, California; 2014
69. Gulley JL, Madan RA, Arlen PM. Enhancing efficacy of therapeutic vaccinations by combination with other modalities. Vaccine 2007;25(Suppl 2):B89-96
70. Gulley JL, Madan RA, Schlom J. Impact of tumor volume on the potential efficacy of therapeutic vaccines. Curr Oncol 2011;18:e150-7
71. NIH-funded study shows increased survival in men with metastatic prostate cancer who receive chemotherapy when starting hormone therapy. National Institutes of Health News & Events. Press release 2013. Available from: Www.nih.gov/news/health/dec2013/nci-05.htm [Last accessed 8 February 2014]
72. Antonarakis ES, Kibel AS, Adams G, et al. A randomized phase II study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): Immune results. American Society of Clinical Oncology Annual Meeting, Chicago, Illinois. J Clin Oncol 2013;31:abstract 5016
73. Dendreon on call. Available from: Www. provengereimbursement.com [Last accessed 7 February 2014]
74. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, doubleblind, placebo-controlled phase 3 study. Lancet Oncol 2012;13:983-92
75. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138-48
76. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2013;367:1187-97
77. Wilson L, Tang Zhong L, Balani G, et al. New therapeutic options in metastatic castration-resistant prostate cancer: Can cost-effectiveness analysis help in treatment decisions? J Oncol Pharm Pract 2013; published online 14 November 2013, doi:10.1177/1078155213509505
78. Chambers JD, Neumann PJ. Listening to Provenge-what a costly cancer treatment says about future medicare policy. N Engl J Med 2011;364:1687-9
79. Rueters. Medicare to cover Dendreon's prostate drug. 2011. Available from: Www.reuters.com/ article/2011/06/30/dendreonprovengeidUSN1E75T1LH20110630 [Last accessed 7 February 2014]
80. Holko P, Kawalec P. Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer. Expert Rev Anticancer Ther 2014;14:63-73
81. Simoens S. Pharmaco-economic aspects of sipuleucel-T. Hum Vaccin Immunother 2012;8:506-8
82. Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol 2008;26:242-5
83. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20
84. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant prostate cancer progressing after docetaxel treatment: A randomised openlabel trial. Lancet 2010;376:1147-54
85. Parker C, Nilsson S, Heinrick D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213-23
86. Tomasz M, Beer AJ, Armstrong CN, et al. Enzalutamide in men with chemotherapy-nai?ve metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study. Genitourinary Cancers Symposium, San Francisco, California. J Clin Oncol 2014;32(Suppl 4):abstract LBA1.